Optimizing Microdosing and Meditation (OMM)

This randomised controlled trial (n=24) will investigate the feasibility of combining meditation with psilocybin microdosing in healthy adults, comparing a group receiving only psilocybin microdoses to a group receiving both psilocybin microdoses and meditation training.

The study, conducted by the National University of Natural Medicine in Portland, Oregon, aims to assess recruitment, retention, acceptability, safety and tolerability of this combined intervention. All participants will receive psilocybin microdoses twice weekly for two weeks, with half randomly selected to also participate in weekday morning online meditation sessions.

The researchers will collect data on sleep quality, heart rate variability and other biometrics using Oura rings, as well as quality of life scores and qualitative feedback. This trial takes advantage of Oregon’s legal psilocybin services programme to study these interventions in a real-world context.

The researchers hypothesise that if the model proves feasible, it could potentially lead to a safe, effective and low-cost intervention combining group meditation with psilocybin microdosing for mental health challenges like depression.

Status Not yet recruiting
Results Published No
Start date 01 October 2024
End date 01 November 2025
Phase Not Applicable
Design Open
Type Interventional
Generation First
Participants 24
Sex All
Age 21- 99
Therapy No

Trial Details

The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2. Acceptability, Safety and Tolerability 3. Exploratory Measures: 3.1: Explore potential changes in sleep quality and duration, heart rate variability, and other biometric outcomes captured by the Oura Ring (3rd generation). 3.2: Explore potential changes in quality of life scores 3.3: Explore potential differences in altered states of consciousness across groups 3.4: Explore qualitative data collected during sessions and at follow-up to assess satisfaction and receive feedback about the intervention. Every participant will receive the psilocybin microdosing intervention, however, half of the participants will be randomly selected to receive the meditation intervention.

NCT Number NCT06560658

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.